Jump to content

Picoplatin: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
Arcadian (talk | contribs)
163,050 edits
Citation bot (talk | contribs)
Bots
5,270,392 edits
Add: pages, issue. Removed parameters. | Use this bot. Report bugs. | Suggested by Abductive | #UCB_webform 305/373
 
(25 intermediate revisions by 19 users not shown)
Line 1: Line 1:
{{orphan|date=April 2010}}

{{chembox
{{chembox
| Verifiedfields = changed
| Verifiedfields = changed
| UNII_Ref = {{fdacite|changed|FDA}}
| Watchedfields = changed
⚫
| verifiedrevid = 444934628
⚫
| UNII = B5TAN0L720
⚫
| verifiedrevid = 387623931
| ImageFile = Picoplatin.png
| ImageFile = Picoplatin.png
| ImageSize = 150px
| ImageSize = 150px
| IUPACName = azane; 2-methylpyridine; platinum(2+); dichloride
| IUPACName = azane; 2-methylpyridine; platinum(2+); dichloride
| OtherNames =
| OtherNames =
| Section1 = {{Chembox Identifiers
|Section1={{Chembox Identifiers
| UNII_Ref = {{fdacite|correct|FDA}}
⚫
| UNII = B5TAN0L720
| CASNo_Ref = {{cascite|correct|??}}
| CASNo = 181630-15-9
| CASNo = 181630-15-9
| PubChem = 177358
| PubChem = 177358
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
⚫
| SMILES = CC1=CC=CC=N1.N.[Cl-].[Cl-].[Pt+2]
| ChemSpiderID = 154428
⚫
| SMILES = Cc1ccccn1.N.[Cl-].[Cl-].[Pt+2]
| SMILES_Comment = ionic form
| SMILES1 = Cl[Pt-2](Cl)([NH3+])[n+]1ccccc1C
| SMILES1_Comment = coordination form
| InChI = 1/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2
| InChIKey = IIMIOEBMYPRQGU-NUQVWONBAG
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = IIMIOEBMYPRQGU-UHFFFAOYSA-L
}}
}}
| Section2 = {{Chembox Properties
|Section2={{Chembox Properties
| C=6|H=10|Cl=2|N=2|Pt=1
| C=6 | H=10 | Cl=2 | N=2 | Pt=1
| Appearance =
| Appearance =
| Density =
| Density =
Line 22: Line 33:
| BoilingPt =
| BoilingPt =
| Solubility = }}
| Solubility = }}
| Section3 = {{Chembox Hazards
|Section3={{Chembox Hazards
| MainHazards =
| MainHazards =
| FlashPt =
| FlashPt =
| Autoignition = }}
| AutoignitionPt = }}
}}
}}


'''Picoplatin''' is a [[Cytotoxicity|cytotoxic]] [[platinum]] compound in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid [[tumor]]s<ref>[http://dx.doi.org/10.1039/C0DT00292E The status of platinum anticancer drugs in the clinic and in clinical trials] Dalton Transactions</ref>.
'''Picoplatin''' is a [[platinum-based antineoplastic agent]] in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid [[tumor]]s.<ref>{{cite journal | doi = 10.1039/C0DT00292E | volume=39 | title=The status of platinum anticancer drugs in the clinic and in clinical trials | year=2010 | journal=Dalton Transactions | last1 = Wheate | first1 = Nial J.| issue=35 | pages=8113–8127 | url=https://ses.library.usyd.edu.au/bitstream/2123/9269/2/41%20Dalton%20perspective.pdf | pmid=20593091 | hdl=2123/14271 | hdl-access=free }}</ref>


In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.<ref>[http://www.poniard.com/programs/picoplatin/clinical.html Picoplatin Clinical Results], Poniard Pharmaceuticals</ref> However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced [[small cell lung cancer]].<ref>[http://www.fiercebiotech.com/story/breaking-news-poniard-shares-crash-phiii-picoplatin-failure/2009-11-16 Poniard shares crash on Phase III picoplatin failure], fiercebiotech.com, November 16, 2009</ref> Hopes are now pinned on its use for metastatic [[colorectal cancer]]<ref>http://www.genengnews.com/specialreports/sritem.aspx?oid=69418732 Nov 2009</ref>.
In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.<ref>[http://www.poniard.com/programs/picoplatin/clinical.html Picoplatin Clinical Results], Poniard Pharmaceuticals</ref> However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced [[small cell lung cancer]].<ref>[http://www.fiercebiotech.com/story/breaking-news-poniard-shares-crash-phiii-picoplatin-failure/2009-11-16 Poniard shares crash on Phase III picoplatin failure], fiercebiotech.com, November 16, 2009</ref> Hopes are now pinned on its use for metastatic [[colorectal cancer]].<ref>http://www.genengnews.com/specialreports/sritem.aspx?oid=69418732 Nov 2009</ref>


== References ==
== References ==
{{Reflist}}
{{Reflist}}
⚫
{{Platinum compounds}}


[[Category:Alkylating antineoplastic agents]]
[[Category:Platinum(II) compounds]]
⚫
[[Category:Platinum compounds]]
[[Category:Organochlorides]]
[[Category:Organochlorides]]
[[Category:Pyridines]]
[[Category:Pyridines]]
[[Category:Platinum-based antineoplastic agents]]




Latest revision as of 17:10, 1 June 2022

Picoplatin
Names
IUPAC name
azane; 2-methylpyridine; platinum(2+); dichloride
Identifiers
3D model (JSmol)
ChemSpider
ECHA InfoCard 100.205.233 Edit this at Wikidata
UNII
  • InChI=1S/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2 ☒N
    Key: IIMIOEBMYPRQGU-UHFFFAOYSA-L ☒N
  • InChI=1/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2
    Key: IIMIOEBMYPRQGU-NUQVWONBAG
  • ionic form: Cc1ccccn1.N.[Cl-].[Cl-].[Pt+2]
  • coordination form: Cl[Pt-2](Cl)([NH3+])[n+]1ccccc1C
Properties
C6H10Cl2N2Pt
Molar mass 376.14 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Picoplatin is a platinum-based antineoplastic agent in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid tumors.[1]

In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.[2] However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced small cell lung cancer.[3] Hopes are now pinned on its use for metastatic colorectal cancer.[4]

References

[edit]
  1. ^ Wheate, Nial J. (2010). "The status of platinum anticancer drugs in the clinic and in clinical trials" (PDF). Dalton Transactions. 39 (35): 8113–8127. doi:10.1039/C0DT00292E. hdl:2123/14271. PMID 20593091.
  2. ^ Picoplatin Clinical Results, Poniard Pharmaceuticals
  3. ^ Poniard shares crash on Phase III picoplatin failure, fiercebiotech.com, November 16, 2009
  4. ^ http://www.genengnews.com/specialreports/sritem.aspx?oid=69418732 Nov 2009


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Picoplatin&oldid=1091007339"